TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04209543
Drug: Progesterone
Normalized name: Progesterone
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Progesterone oral tablet: administered orally once daily
Study: NCT03514771
Drug: oral valacyclovir
DrugBank: Acyclovir (DB00787)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral valacyclovir
Study: NCT02419937
Drug: Tocilizumab
Normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 162 mg subcutaneously once (vs. 0.9% normal saline placebo injection once in placebo arm)
Study: NCT00813293
Drug: Sorafenib
Normalized name: Sorafenib
DrugBank: Sorafenib (DB00398)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00004907
Drug: busulfan
Normalized name: Busulfan
DrugBank: Busulfan (DB01008)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00004907
Drug: etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02924883
Drug: Atezolizumab
Normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Atezolizumab 1200 mg IV infusion
Study: NCT02924883
Drug: Trastuzumab emtansine
Normalized name: Trastuzumab emtansine
DrugBank: Trastuzumab emtansine (DB05773)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Trastuzumab emtansine 3.6 mg/kg IV infusion
Study: NCT01135927
Drug: insulin degludec
Normalized name: Insulin Degludec
DrugBank: Insulin degludec (DB09564)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: NN1250 (insulin degludec) injected s.c. (under the skin) once daily for 6 days
Study: NCT01135927
Drug: insulin detemir
Normalized name: Insulin Detemir
DrugBank: Insulin detemir (DB01307)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Insulin detemir injected s.c. (under the skin) once daily for 6 days
Study: NCT01243281
Drug: PEG-IFN and entecavir
Normalized name: PEG IFN-beta-1a
DrugBank: Entecavir (DB00442)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The patients will be randomized in approximately 1:1 ratio into one of 2 treatment regimens; to receive PEG-IFN alpha-2b (1.5 microgram/kg/week) plus entecavir (0.5 mg/day) or PEG-IFN alpha-2b (1.5 microgram/kg/week) alone for 48 weeks by using pre-generated randomization schedule.
Study: NCT02670824
Drug: CN-105
Normalized name: CN-105
DrugBank: CN-105 (DB18345)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single and multiple intravenous (IV) doses of CN-105
Study: NCT01330134
Drug: lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2ml 1% lidocaine placed onto surface of the skin immediately prior to 1% lidocaine subcutaneous injection
Study: NCT01330134
Drug: lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1% lidocaine subcutaneous injection alone
Study: NCT04162821
Drug: Hydronidone
Normalized name: Hydronidone
DrugBank: Hydronidone (DB06299)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Take hydroxynitone capsule
Study: NCT01514487
Drug: liraglutide
Normalized name: Liraglutide
DrugBank: Liraglutide (DB06655)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: One single dose of 0.75 mg administered on three different dosing occasions with a 14-day wash-out period between each dosing. Injected subtaneously
Study: NCT01944293
Drug: Ketamine
Normalized name: Ketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single dose of 0.5 mg/kg of Ketamine given intravenously (in the vein) over 40 minutes
Study: NCT01944293
Drug: Midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Single dose of 0.02 mg/kg of Midazolam given intravenously (in the vein) over 40 minutes
Study: NCT02293668
Drug: Letrozole 5mg and hMG 150IU
Normalized name: letrozole 2.5 MG
DrugBank: Letrozole (DB01006)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02175238
Drug: BI 691751 fasted
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: single dose BI 691751 in fasted state
Study: NCT02914600
Drug: Filgotinib
Normalized name: Filgotinib
DrugBank: Filgotinib (DB14845)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: Tablet administered orally once a day
Study: NCT00354198
Drug: pentoxifylline
Normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: intravenous pentoxifylline (0.33-0.66 mg/kg/h from days 1 to 7) followed by oral pentoxifylline 400-800 mg/day (from days 8-90). The dose of intravenous pentoxifylline will be determined by estimated GFR, patients whose GFRs are 30-59 ml/min/1.73 m2 will be given 0.66 mg/kg/h, and those below 30 ml/min/1.73 m2 will be given 0.33 mg/kg/h. The oral dose of pentoxifylline will also be determined by estimated GFR. Patients whose estimated GFRs are between 30-59 ml/min/1.73 m2 will be given 800 mg/day, and those below 30 ml/min/1.73 m2 will be given 400 mg/day.
Study: NCT01159132
Drug: raltegravir
Normalized name: Raltegravir
DrugBank: Raltegravir (DB06817)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 12 hour PK will be done on day 1 while subjects is on stable regimen with RAL 400 mg BID. After performing intensive PK, subjects will be randomized to either group A (RAL 400 mg OD) or B (RAL 800 mg OD) for 14 days and on day 15, a second 24 hour full PK will be carried out. After the intensive PK, subjects in both the groups will switched to the other dosing regimen, group A (RAL 800 mg OD) and B (RAL 400 mg OD) for another 14 days and on day 29, the third 24 hour full PK will be carried out.
Study: NCT01121276
Drug: Faster-acting insulin aspart
Normalized name: diphenhydramine
DrugBank: Insulin aspart (DB01306)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 0.2 U/kg body weight injected subcutaneously (under the skin)
Study: NCT01121276
Drug: insulin aspart
Normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 0.2 U/kg body weight injected subcutaneously (under the skin)
Study: NCT04389320
Drug: Hydroxychloroquine
Normalized name: Hydroxychloroquine
DrugBank: Hydroxychloroquine (DB01611)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: assess its role in the coarse of covid 19 virus infection
Study: NCT04334174
Drug: Brentuximab Vedotin
Normalized name: Brentuximab Vedotin
DrugBank: Brentuximab vedotin (DB08870)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Brentuximab Vedotin will be dosed at 1.8 milligram (mg) per (/) kilogram (Kg) of participants body weight will be infused intravenously every three weeks for up to ten infusions.
Study: NCT02457520
Drug: Isotretinoin
Normalized name: Isotretinoin
DrugBank: Isotretinoin (DB00982)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ABSORICA® (isotretinoin) capsules 0.5 mg/kg/day for 4 weeks followed by 1.0 mg/kg/day for 16 weeks
Study: NCT03488667
Drug: Neoadjuvant Treatment - mFOLFOX6 & Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pembrolizumab, mFOLFOX Chemotherapy
Study: NCT03488667
Drug: Adjuvant Treatment - mFOLFOX & Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pembrolizumab, mFOLFOX Chemotherapy
Study: NCT01305226
Drug: THR-100
Normalized name: Thr
DrugBank: Threonine (DB00156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: THR-100: 15 mg double-bolus (15mg/15ml), separated by 30 minutes (total 30 mg)
Study: NCT01305226
Drug: Streptokinase
Normalized name: Streptokinase
DrugBank: Streptokinase (DB00086)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Streptokinase: Standard regimen (1.5 million IU) is made up in 150 ml of physiological saline or glucose solution and administered intravenously over a period of 60 minutes.
Study: NCT00282048
Drug: AG-013736 (axitinib)
Normalized name: Axitinib
DrugBank: Axitinib (DB06626)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: AG-013736 5 mg twice daily \[bid\] continuous dosing in 28 day cycles.
Study: NCT04714242
Drug: Ranibizumab Injection
Normalized name: ranibizumab Injection
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Three monthly intravitreal injections of Ranibizumab
Study: NCT02768337
Drug: Afatinib
Normalized name: Afatinib
DrugBank: Afatinib (DB08916)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT01185548
Drug: Tolbutamide
Normalized name: Tolbutamide
DrugBank: Tolbutamide (DB01124)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered orally
Study: NCT01185548
Drug: Tasisulam
Normalized name: Tasisulam
DrugBank: Tasisulam (DB11941)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered intravenously
Study: NCT03395548
Drug: Macrogol
Normalized name: Macrogol
DrugBank: Polyethylene glycol (DB09287)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Used drug: Macrogol (osmotic laxative)
Study: NCT02225470
Drug: E7389 (Eribulin Mesylate)
Normalized name: Eribulin Mesylate
DrugBank: Eribulin (DB08871)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT02225470
Drug: Vinorelbine injection
Normalized name: vinorelbine Injection
DrugBank: Vinorelbine (DB00361)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00003281
Drug: paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00003281
Drug: topotecan hydrochloride
Normalized name: Topotecan Hydrochloride
DrugBank: Topotecan (DB01030)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03717350
Drug: Meropenem
Normalized name: Meropenem
DrugBank: Meropenem (DB00760)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2g of meropenem diluted in 100ml of sodium chloride 0.9% within 15 minutes intravenously administered once
Study: NCT00259012
Drug: pantoprazole sodium enteric-coated spheroid suspension
Normalized name: pantoprazole
DrugBank: Pantoprazole (DB00213)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: pediatric suspension taken daily x 7 days
Study: NCT00659321
Drug: nicotine acid
Normalized name: NICOTINIC ACID
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 16 weeks, randomisation with 500 mg, after 4 weeks elevation of 1000 mg, after week 8 to week 16 1500 mg study medication
Study: NCT02458469
Drug: Buspirone
Normalized name: Buspirone
DrugBank: Buspirone (DB00490)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The initial dose of Buspirone is 15 mg daily (7.5 mg bid.). To achieve an optimal therapeutic response, at intervals of 2 to 3 days the dosage may be increased 5 mg per day until a maximum dose 30mg/day is reached.
Study: NCT02458469
Drug: Trazodone
Normalized name: Trazodone
DrugBank: Trazodone (DB00656)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100 mg dose before bed-time
Study: NCT00743483
Drug: rhBSSL
Normalized name: rhBSSL
DrugBank: Bucelipase alfa (DB16664)
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral suspension, 170 mg BSSL, 3 times daily for 5-6 days
Study: NCT02916290
Drug: UDCA
Normalized name: UDCA
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01813006
Drug: Omega-3
Normalized name: Omega-3
DrugBank: Omega-3 fatty acids (DB11133)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02149888
Drug: Tenofovir/emtricitabine
DrugBank: Emtricitabine (DB00879)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Once daily Tenofovir/emtricitabine (Truvada®)
Study: NCT03027115
Drug: Tamsulosin
Normalized name: Tamsulosin
DrugBank: Tamsulosin (DB00706)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tamsulosin treatment for 7 days pre-operatively
Study: NCT00398515
Drug: lenalidomide
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given orally
Study: NCT00398515
Drug: temsirolimus
Normalized name: Temsirolimus
DrugBank: Temsirolimus (DB06287)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given IV
Study: NCT01586611
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1000 mg/m2 IV weekly for 3 weeks then one week off
Study: NCT01612871
Drug: Tamoxifen, Letrozole , Anastrozole, Exemestane
DrugBank: Tamoxifen (DB00675)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Current first line metastatic hormone therapy treatment in hormone dependent breast cancer :~Tamoxifen 20 mg/day, Letrozole 2.5 mg/day, Anastrozole 1 mg/day, Exemestane 25mg/day
Study: NCT02798874
Drug: Ticagrelor
Normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ticagrelor 180 mg 30 min before PCI and 90 mg for 12 months after surgery
Study: NCT02798874
Drug: Clopidogrel
Normalized name: Clopidogrel
DrugBank: Clopidogrel (DB00758)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Clopidogrel 600 mg 30 min before PCI and 75 mg for 12 months after surgery
Study: NCT00004562
Drug: Beta adrenergic blockers
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive beta adrenergic blockers.
Study: NCT00567762
Drug: FK506
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Opthalmic suspension
Study: NCT02964260
Drug: Chemotherapy drug
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxorubicin/Platinum agents
Study: NCT00720265
Drug: Prograf
Normalized name: Prograf
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral
Study: NCT00720265
Drug: MR4
Normalized name: HMR4011
DrugBank: HMR4011 (DB06225)
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral
Study: NCT01387022
Drug: Tenofovir, lamivudine and efavirenz
DrugBank: Efavirenz (DB00625)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tenofovir, 300mg daily, lifelong Lamivudine, 300mg daily, lifelong Efavirenz, 600mg daily, lifelong
Study: NCT00376623
Drug: BI 2536
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous Infusion
Study: NCT00819507
Drug: Fluocinonide
Normalized name: Fluocinonide
DrugBank: Fluocinonide (DB01047)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluocinonide 0.1% cream topical daily for two weeks
Study: NCT03723395
Drug: tucatinib
Normalized name: Tucatinib
DrugBank: Tucatinib (DB11652)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 300mg dose, orally administered
Study: NCT03723395
Drug: itraconazole
Normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 200mg dose
Study: NCT03723395
Drug: rifampin
Normalized name: Rifampin
DrugBank: Rifampin (DB01045)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600mg dose
Study: NCT03723395
Drug: gemfibrozil
Normalized name: Gemfibrozil
DrugBank: Gemfibrozil (DB01241)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 600mg tablets
Study: NCT03723395
Drug: repaglinide
Normalized name: Repaglinide
DrugBank: Repaglinide (DB00912)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1mg dose
Study: NCT03723395
Drug: tolbutamide
Normalized name: Tolbutamide
DrugBank: Tolbutamide (DB01124)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 500mg dose
Study: NCT03723395
Drug: midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 2mg dose
Study: NCT03723395
Drug: digoxin
Normalized name: Digoxin
DrugBank: Digoxin (DB00390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.5 mg dose
Study: NCT01084083
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given IV, 90 mg/m\^2 on days 1, 8 and 15
Study: NCT01084083
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV, 75 mg/m\^2 on day 1
Study: NCT00272740
Drug: Fulvestrant
Normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT01371786
Drug: ciclesonide nasal aerosol
Normalized name: Ciclesonide Nasal Aerosol
DrugBank: Ciclesonide (DB01410)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A radiolabeled solution of ciclesonide nasal aerosol supplied in a 37 μg/actuation canister
Study: NCT01371786
Drug: mometasone Aqueous (AQ) nasal spray
Normalized name: mometasone Metered Dose Nasal Spray
DrugBank: Mometasone (DB00764)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A radiolabeled suspension of mometasone Aqueous (AQ) nasal spray supplied in a 50 μg/actuation bottle
Study: NCT00344110
Drug: Aliskiren
Normalized name: Aliskiren
DrugBank: Aliskiren (DB09026)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02099981
Drug: Aminoguanidine
Normalized name: Aminoguanidine
DrugBank: Pimagedine (DB05383)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04400123
Drug: Famitinib malate
Normalized name: malate
DrugBank: Famitinib (DB11741)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TR group:~The first period，the subjects will be administrated with Famitinib malate in new formulation, then conduct blood collection within 192h; 14 days washout；The second period，the subjects will be administrated with Famitinib malate in old formulation, then conduct blood collection within 192h.~RT group:~The first period，the subjects will be administrated with Famitinib malate in old formulation, then conduct blood collection within 192h; 14 days washout；The second period，the subjects will be administrated with Famitinib malate in new formulation, then conduct blood collection within 192h.
Study: NCT02420210
Drug: Bendamustine Hydrochloride
Normalized name: Bendamustine Hydrochloride
DrugBank: Bendamustine (DB06769)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT02420210
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given PO
Study: NCT02469805
Drug: Merional
Normalized name: Meriones unguiculatus skin
DrugBank: Meriones unguiculatus skin (DB10603)
Approvals — FDA: no, EMA: no, PMDA: no
Description: On the 3rd day of menstruation women will have a vaginal ultrasound and will receive daily intramuscular 150 IU of human menopausal gonadotropins (hMG, Merional ®, IBSA, Lugano, Switzerland) starting from the 3nd day of menstruation.
Study: NCT03527147
Drug: Acalabrutinib
Normalized name: Acalabrutinib
DrugBank: Acalabrutinib (DB11703)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Acalabrutinib will be administered orally twice daily (bid).
Study: NCT03527147
Drug: Hu5F9-G4
Normalized name: Anti-cd47 monoclonal antibody hu5f9-g4
DrugBank: Magrolimab (DB16225)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HU5F9-G4 infusions will be given on Weekly (Day 1, 8, 15, and 22) during the first two 28-day cycles, then will be given every two weeks (Day 1 and Day 15) in Cycle 3 and beyond.
Study: NCT03527147
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab infusions will be given Weekly starting on Day 8 (Day 8, 15, and 22) during the first 28-day cycle (4 weeks), then Day 1 of each 4 week cycle for Cycles 2-6. Starting with Cycle 8, Rituximab will be infused on Day 1 of every other cycle (every 8 weeks).
Study: NCT00336479
Drug: Telaprevir
Normalized name: Telaprevir
DrugBank: Telaprevir (DB05521)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: tablet
Study: NCT00336479
Drug: Ribavirin
Normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: tablet
Study: NCT00336479
Drug: Pegylated Interferon Alfa 2a
Normalized name: Pegylated-interferon alfa 2a
DrugBank: Interferon alfa (DB05258)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution for injection
Study: NCT02967159
Drug: Abediterol
Normalized name: Abediterol
DrugBank: Abediterol (DB12100)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment A: Abediterol 2.5 μg via DPI
Study: NCT02967159
Drug: AZD7594/abediterol
DrugBank: Abediterol (DB12100)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment C: AZD7594/abediterol 440 μg/2.5 μg FDC via DPI
Study: NCT02967159
Drug: AZD7594 and abediterol
Normalized name: cytarabine and daunorubicin
DrugBank: Abediterol (DB12100)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment D: AZD7594 440 μg and abediterol 2.5 μg free combination administered via 2 separate DPIs
Study: NCT00507663
Drug: Atenolol
Normalized name: Atenolol
DrugBank: Atenolol (DB00335)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients with a standing prescription for β-blockers will be continued on that medication. Pts not currently receiving a beta blocker will be given 50mg of atenolol on the morning of surgery, 50-100mg, twice per day, on the first postoperative day until postoperative day 7.
Study: NCT02914119
Drug: Rocuronium
Normalized name: Rocuronium
DrugBank: Rocuronium (DB00728)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02914119
Drug: Succinylcholine
Normalized name: Succinylcholine
DrugBank: Succinylcholine (DB00202)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02914119
Drug: Cisatracurium
Normalized name: Cisatracurium
DrugBank: Cisatracurium (DB00565)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02914119
Drug: Mivacurium
Normalized name: Mivacurium
DrugBank: Mivacurium (DB01226)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00550537
Drug: bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 15 mg/m2 given through a vein for every 3 weeks
Study: NCT00550537
Drug: carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: AUC = 6 given through a vein on day 1 of each cycle.
Study: NCT00550537
Drug: erlotinib hydrochloride
Normalized name: Erlotinib Hydrochloride
DrugBank: Erlotinib (DB00530)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 150 mg taken by mouth daily
Study: NCT00550537
Drug: paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 200 mg/m2 given through a vein on day 1 of each cycle.
Study: NCT02914119
Drug: Sugammadex
Normalized name: Sugammadex
DrugBank: Sugammadex (DB06206)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT02914119
Drug: Neostigmine
Normalized name: Neostigmine
DrugBank: Neostigmine (DB01400)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00861120
Drug: Panitumumab
Normalized name: Panitumumab
DrugBank: Panitumumab (DB01269)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 6 mg/kg on days 1 and 15 of a 28 days cycle
Study: NCT01497470
Drug: Custirsen, paclitaxel and carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Custirsen (640 mg IV over 2 hours) will be administered weekly on Days 1, 8, and 15 of each 21 day cycle. Paclitaxel (200 mg/m2 IV over 3 hours) and carboplatin (AUC 6.0 mg/mL/min IV over 30 minutes) will be administered on Day 1 of each 21 day cycle
Study: NCT00483561
Drug: Gefitinib plus etoposide
DrugBank: Gefitinib (DB00317)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gefitinib 250 mg p.o. daily, starting on Day 1and taken on a continuous basis throughout the trial with Etoposide 50 mg/m2/day for Days 1-14 out of a 28-day cycle. (Etoposide capsules come in a 50-mg dose formulation, and the patient's dose will be rounded to the nearest 50-mg multiple).
Study: NCT00338481
Drug: Morphine p.o.
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Morphine p.o. in red morphine drops calculated as 1/12 of the 24 hours opioid consumption converted to morphine p.o., max. 24 mg morphine p.o.and isotonic sodium chloride s.c.